Johnson & Johnson's Trispecific Antibody Show Promising Response In Myeloma Patients
3/6 17:05
(RTTNews) - Johnson & Johnson (JNJ) announced Tuesday initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma....